FUSEN PHARM(01652): "Nicardipine hydrochloride injection" consistency evaluation application approved for listing.

FUSEN PHARM (01652) announced that the consistency evaluation application for "Nicardipine Hydrochloride Injection" developed by its wholly-owned subsidiary, Henan FUSEN PHARM Co., Ltd., has been approved by the China National Medical Products Administration for emergency management of hypertension during surgery and hypertensive emergencies. According to data from Meini.com, the terminal sales of Nicardipine Hydrochloride Injection in public medical institutions in China exceeded 600 million RMB in 2024, with rapid expansion in the sales scale of the top three terminals and six major markets in recent years. The sales growth rate from 2022 to 2024 will remain in double digits, with year-on-year increases of 35.71%, 16.09%, and 14.14%, respectively. Nicardipine Hydrochloride is a novel dihydropyridine calcium ion antagonist that selectively dilates arteries to achieve rapid and stable control of hypertensive emergencies. Nicardipine Hydrochloride Injection is recommended as a first-line treatment drug for specific hypertension management situations in the 2020 International Hypertension Society's "Global Hypertension Practice Guidelines," as well as the most widely recommended first-line intravenous antihypertensive drug in the "Chinese Guidelines for the Diagnosis and Treatment of Hypertensive Emergencies," receiving recommendations from various guidelines both domestically and internationally. Nicardipine Hydrochloride Injection has advantages such as rapid onset of action, stable blood pressure reduction, more comprehensive protection of target organs, non-toxic metabolites, safe application, stronger vascular selectivity, no effects on heart rhythm, safer for the myocardium, and a dual balance of blood pressure reduction and perfusion. The 5ml:5mg specification of Nicardipine Hydrochloride Injection developed by the group has been sold in the domestic market for many years and has high market acceptance. The specifications approved at the same time are 2ml:2mg and 10ml:10mg, making FUSEN PHARM one of the domestic companies with the most comprehensive range of product specifications, able to meet the treatment needs of different patients simultaneously. The quality and efficacy of Nicardipine Hydrochloride Injection held by FUSEN PHARM are consistent with reference products, and can be used as a substitute for the original drug in clinical practice. Nicardipine Hydrochloride Injection has shown very favorable prospects in the emergency management of hypertension during surgery and hypertensive emergencies.